Atezolizumab Could Change Standard of Care in Bladder CancerAtezolizumab Could Change Standard of Care in Bladder Cancer

Updated results from the IMvigor 210 trial demonstrate durable responses in metastatic urothelial cancer, even in patients with poor prognostic factors. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news